Long-term endothelial cell loss with the iris-claw intraocular phakic lenses (Artisan®)
To evaluate the endothelial cell loss in patients with iris-claw phakic lenses (Artisan®) in a long-term follow-up.
We analyzed the medical records of patients who had undergone iris-claw phakic lens implantation and who had at least 5 years of follow-up.
We included 67 eyes with myopic errors (follow-up 9.6 ± 3.0 years) and 10 eyes with mixed astigmatism or hyperopic errors (follow-up 8.8 ± 2.5 years). The mean total endothelial density loss at the last follow-up visit was 18.5% ± 17.0% and 10.5% ± 12.3%, respectively. 29.9% of the eyes in the myopic group and 20% in the hyperopic group lost more than 25% of the preoperative endothelial cell density. During the postoperative follow-up period, 60.8% of the eyes in the myopic group and 40% of the eyes in the hyperopic group lost a higher percentage than the expected physiological loss. Two eyes in the myopic group (3.0%) had a final cell density of less than 1200 cells/mm2. None of the variables studied had a statistically significant association with the percentage of annual endothelial loss in the postoperative period. Three phakic lenses were explanted: two by cataract and one by cataract and severe decrease of the endothelial density (862 cells/mm2).
There is a significant endothelial cell loss in a low percentage of the eyes with Artisan® lenses in the long term, and it can decrease to critical levels. Periodic endothelial density evaluations are required for these patients. The selection criteria of surgical candidates could be reevaluated.
KeywordsPhakic intraocular lenses Corneal endothelial cell loss Corneal edema Refractive surgery Corneal endothelium Cornea
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in this study involving human participants were in accordance with the ethical standards of Fundacion Oftalmológica de Santander FOSCAL and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Vega-Estrada A, Alió JL, Arba Mosquera S, Moreno LJ (2012) Corneal higher order aberrations after LASIK for high myopia with a fast repetition rate excimer laser, optimized ablation profile, and femtosecond laser-assisted flap. J Refract Surg 28:689–696. https://doi.org/10.3928/1081597X-20120921-03 CrossRefPubMedGoogle Scholar
- 10.Alió JL, Abbouda A, Peña-Garcia P, Huseynli S (2013) Follow-up study of more than 15 years of an angle-supported phakic intraocular lens model (ZB5M) for high myopia outcomes and complications. JAMA Ophthalmol 131:1541–1546. https://doi.org/10.1001/jamaophthalmol.2013.5595 CrossRefPubMedGoogle Scholar
- 12.Sayman Muslubas IB, Kandemir B, Aydin Oral AY, Kugu S, Dastan M (2014) Long-term vision-threatening complications of phakic intraocular lens implantation for high myopia. Int J Ophthalmol 7:376–380. https://doi.org/10.3980/j.issn.2222-3959.2014.02.32 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Stulting RD, John ME, Maloney RK, Assil KK, Arrowsmith PN, Thompson VM (2008) Three-year results of Artisan/Verisyse phakic intraocular lens implantation. Results of the United States Food and Drug Administration Clinical Trial. Ophthalmology 115:464–472. https://doi.org/10.1016/j.ophtha.2007.08.039 CrossRefPubMedGoogle Scholar
- 23.Jonker SMR, Berendschot TTJM, Ronden AE, Saelens IEY, Bauer NJC, Nuijts RMMA (2018) Long-term endothelial cell loss in patients with Artisan myopia and Artisan toric phakic intraocular lenses: 5- and 10-year results. Ophthalmology 125:486–494. https://doi.org/10.1016/j.ophtha.2017.08.011 CrossRefPubMedGoogle Scholar
- 29.Alfonso JF, Fernández-Vega-Cueto L, Alfonso-Bartolozzi B, Montés-Micó R, Fernández-Vega L (2019) Five-year follow-up of correction of myopia: posterior chamber phakic intraocular lens with a central port design. J Refract Surg 35:169–176. https://doi.org/10.3928/1081597X-20190118-01 CrossRefPubMedGoogle Scholar
- 31.Gierek-Ciaciura S, Gierek-Lapinska A, Ochalik K, Mrukwa-Kominek E (2007) Correction of high myopia with different phakic anterior chamber intraocular lenses: ICARE angle-supported lens and Verisyse iris-claw lens. Graefes Arch Clin Exp Ophthalmol 245:1–7. https://doi.org/10.1007/s00417-006-0374-7 CrossRefPubMedGoogle Scholar
- 40.Moshirfar M, Imbornoni LM, Ostler EM, Muthappan V (2014) Incidence rate and occurrence of visually significant cataract formation and corneal decompensation after implantation of Verisyse/Artisan phakic intraocular lens. Clin Ophthalmol 8:711–716. https://doi.org/10.2147/OPTH.S59878 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Sikder S, Patel V, Holz HA, Mifflin MD, Davis S, Moshirfar M (2011) Management of corneal endothelial decompensation caused by iris-claw phakic intraocular lenses with descemet stripping automated endothelial keratoplasty. Cornea 30:1045–1047. https://doi.org/10.1097/ICO.0b013e3182035dd0 CrossRefPubMedGoogle Scholar
- 45.Bouheraoua N, Bonnet C, Labbé A, Sandali O, Lecuen N, Ameline B, Borderie V, Laroche L (2015) Iris-fixated phakic intraocular lens implantation to correct myopia and a predictive model of endothelial cell loss. J Cataract Refract Surg 41:2450–2457. https://doi.org/10.1016/j.jcrs.2015.05.030 CrossRefPubMedGoogle Scholar
- 46.Shajari M, Scheffel M, Koss MJ, Kohnen T (2016) Dependency of endothelial cell loss on anterior chamber depth within first 4 years after implantation of iris-supported phakic intraocular lenses to treat high myopia. J Cataract Refract Surg 42:1562–1569. https://doi.org/10.1016/j.jcrs.2016.08.027 CrossRefPubMedGoogle Scholar
- 49.MacRae S, Holladay JT, Hilmantel G, Calogero D, Masket S, Stark W, Glasser A, Rorer E, Tarver ME, Nguyen T, Eydelman M (2017) Special report: American Academy of Ophthalmology Task Force Recommendations for specular microscopy for phakic intraocular lenses. Ophthalmology 124:141–142. https://doi.org/10.1016/j.ophtha.2016.09.034 CrossRefPubMedGoogle Scholar
- 50.Bernard P, Fournier M (2006) Definitive stop of marketing, product recall and follow-up of implanted patients. Presbyopia intraocular lenses NEWLIFE/VIVARTE PRESBYOPIC. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), V8. 21/12/06. Available in; https://ansm.sante.fr/content/download/14109/169659/version/1/file/dm070101.pdf.
- 61.Galvis V, Tello A, Delgado J, Gutiérrez AJ, Rodríguez L, Chaparro T (2011) Reproducibility of the results of the endothelial analysis with the Topcon sp-3000p® non-contact specular microscope. Rev Sociedad Colombiana de Oftalmología 44:253–260Google Scholar